Current Report Filing (8-k)
June 06 2019 - 5:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
June 6, 2019
Date of report (date of earliest event reported)
MusclePharm Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
000-53166
|
|
77-0664193
|
(State or other jurisdictions of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Nos.)
|
4400 Vanowen Street
Burbank, CA 91505
(Address of principal executive offices) (Zip Code)
(303) 396-6100
(Registrant’s telephone number, including area
code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrants
under any of the following provisions:
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
N/A
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 4.01
Changes in Registrant’s Certifying Accountant.
On June 6, 2019, the Audit Committee of the Board of Directors of
MusclePharm Corporation (the “Company”) approved the
engagement of SingerLewak LLP (“Singer”) as the
Company’s independent accountant to audit the Company’s
consolidated financial statements for the fiscal year ended
December 31, 2018 and for the fiscal year ending December 31, 2019,
effective immediately.
During the years ended December 31, 2018 and 2017, and the
subsequent interim period through June 6, 2019, neither the Company
nor anyone on its behalf consulted Singer regarding either: (i) the
application of accounting principles to a specific transaction,
either completed or proposed; or the type of audit opinion that
might be rendered on the Company’s financial statements, and
neither a written report was provided to the Company nor oral
advice was provided that Singer concluded was an important factor
considered by the Company in reaching a decision as to any
accounting, auditing or financial reporting issue; or (ii) any
matter that was either the subject of a disagreement (as defined in
Item 304(a)(1)(iv) of Regulation S-K and the related instructions)
or a reportable event (as described in Item 304(a)(1)(v) of
Regulation S-K).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
MUSCLEPHARM CORPORATION
|
|
|
|
|
By:
|
/s/
Ryan Drexler
|
|
|
|
Name:
Ryan Drexler
Title:
Chief Executive Officer
|
Date:
June 6, 2019
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024